




After decades as a Cinderella discipline, valvular heart disease 
(VHD) now occupies the centre stage of cardiovascular medi-
cine. Changing societal demographics and an ageing popula-
tion (with increasing prevalence of degenerative disease), 
advances in imaging and the explosion of interest in tran-
scatheter interventional techniques (supported by a series of 
landmark clinical trials) have attracted clinicians, researchers, 
engineers, device manufacturers and investors, and trans-
formed the landscape of clinical management. In many senses, 
2019 has been a leap year for VHD.
EPIDEMIOLOGICAL TRENDS
The changing demography of VHD and its impact on clinical 
management were highlighted by the EURObservational 
Research Programme VHD II Survey,(1) a contemporary registry 
of 7 247 patients (4 483 hospitalised, 2 764 outpatients) with 
VHD treated at 222 centres in 28 nations. Key findings included 
the rising age of patients with VHD in comparison with a similar 
survey performed in 2005,(2) a high concordance with guideline 
recommendations for patients with aortic valve disease (though 
less so for mitral valve disease where referral for intervention 
was frequently delayed), and the progressive emergence of 
transcatheter interventions (aortic stenosis 39%, mitral regur-
gitation 17%).
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DIAGNOSTIC IMAGING
Multimodality imaging is of fundamental importance in VHD 
for initial diagnosis, monitoring of disease progression (valve 
lesion and associated myocardial remodelling response), plan-
ning of transcatheter and surgical intervention, and subsequent 
follow-up.
The valve
Echocardiography remains the first-line imaging modality in 
VHD. An investigation of inter-observer reproducibility of peak 
velocity and mean gradient measurements in patients with 
aortic stenosis (based on 20 echocardiographic examinations 
assessed by 25 different observers) demonstrated superior 
reproducibility of peak velocity compared with mean gradient 
assessment (coefficient of variation 10.1% vs. 18.0%; p< 0.001), 
suggesting that peak velocity should be the preferred measure 
for tracking the progression of aortic stenosis.(3) Asymptomatic 
patients with a peak velocity >5m/s and ejection fraction <60% 
have increased mortality [even after aortic valve replacement 
(AVR)] and early intervention should be considered in these 
high-risk patients.(4)
European Society of Cardiology (ESC) guidelines recommend 
computed tomography (CT) calcium scoring to assess the 
severity of aortic stenosis when echocardiographic measure-
ments are discordant.(5) Advances in this field include clear 
guidance on optimal scoring of valve calcification(6) and a large 
international multicentre study confirming the diagnostic accu-
racy of this method and its power to predict disease progres-
sion and clinical events.(7)
Positron emission tomography (PET) imaging using 18F-fluoride 
as a marker of calcification activity may detect early biopros-
thetic valve degeneration before it is evident on echocardio-
graphy or CT (Figure  1). Indeed, one study demonstrated 
histological validation of increased tracer uptake by biopros-
thetic leaflets as a marker of degeneration and the only 
independent predictor for future valve dysfunction.(8) How-
ever, the potential for the integration of these findings into 
clinical practice remains uncertain.
The myocardium
Myocardial damage secondary to VHD is being increasingly 













magnetic resonance (CMR) approaches. In primary mitral 
regurgitation (MR), for example, myocardial fibrosis identified 
on CMR is closely associated with increased incidence of ven-
tricular arrhythmias,(9) while impaired echocardiographic global 
longitudinal strain (threshold ≥20.6%) is associated with adverse 
long-term prognosis in subjects undergoing surgery.(10)
Left ventricular mechanical dispersion assessed using speckle 
tracking echocardiography demonstrated incremental prog-
nostic value for all-cause mortality in 630 patients with aortic 
stenosis [hazard ratio (HR) 1.10 (95% confidence interval, 
CI 1.04 - 1.15) per 10ms increase;  p< 0.001].(11)  Similarly, 
reduced endocardial, mid-myocardial, and epicardial longitu-
dinal strain predicted symptomatic status in 211 patients with 
severe aortic stenosis, whilst endocardial longitudinal strain pro-
vided an independent predictor of cardiovascular mortality.(12) 
Extending this concept, a four-stage system for the echocar-
diographic grading of cardiac damage in 735 patients with 
asymptomatic moderate or severe aortic stenosis provided 
incremental prognostic information over and above standard 
clinical variables.(13)
FIGURE 1: In vivo 18F-fluoride positron emission tomography and computed tomography imaging of patients with bio-
prosthetic aortic valves.
Baseline computed tomography (left) and 18F-fluoride positron emission tomography (right) images from patients with bioprosthetic aortic valves. 
En-face computed tomography images of bioprosthetic aortic valves showing spotty and large calcification (top left), circumferential pannus 
(bottom left), and non-calcific leaflet thickening suggestive of thrombus (top right) (all identified by red arrows). Hybrid en-face positron emission 
tomography-computed tomography images in the same patients: Increased bioprosthetic  18F-fluoride activity (red/yellow) colocalise with 
computed tomography abnormalities in each patient. 18F-fluoride activity was also commonly observed remote from leaflet changes on computed 
tomography (bottom right). Target-to-background values are annotated on the hybrid positron emission tomography-computed tomography 





























































Myocardial fibrosis is the major driver of left ventricular decom-
pensation in aortic stenosis and may be directly visualised using 
CMR.(14) Replacement fibrosis progresses rapidly once estab-
lished, persists following valve replacement, and is associated 
with poor long-term prognosis (Figure  2).(15,16)  The ongoing 
EVOLVED trial (NCT03094143) will determine whether 
prompt AVR/transcatheter aortic valve implantation (TAVI) 
can improve clinical outcomes in asymptomatic patients with 
severe aortic stenosis and evidence of early fibrosis.
DEVELOPING MEDICAL THERAPIES
Unlike other major cardiovascular conditions, effective medical 
therapies are lacking for VHD. Intense research has focused 
upon identifying novel therapeutic targets, particularly in aortic 
stenosis. Among 367 703 UK BIOBANK participants, obesity 
was associated with increased risk of aortic stenosis, thereby 
underlining the potential importance of weight reduction as a 
preventive strategy.(17)
Preclinical studies have highlighted the role of platelet activa-
tion in the progression of aortic stenosis,(18)  while Lp(a) is 
associated with increased aortic valve calcification, faster pro-
gression of aortic stenosis, and increased risk of intervention or 
death,(19)  and provides an extremely promising therapeutic 
target. Statins increase Lp(a), however,(20) and tailored treatment 
may prove necessary.
Calcification is the major driver of progressive aortic stenosis 
and the target of novel imaging technologies and potential 
therapeutic strategies, including the ongoing SALTIRE II 
(NCT02132026) and BASIK II (NCT02917525) randomised 
controlled trials.(21)  A Swedish population study of over 1 
million subjects confirmed the association between aortic 
stenosis and chronic kidney disease, presumably related to 
altered calcium and phosphate metabolism,(22)  while a non-
randomised study of 2 785 patients demonstrated greater 
reduction in left ventricular volumes, hypertrophy, and 
cardiovascular mortality associated with the use of renin-
angiotensin system inhibitors following TAVI.(23)  Randomised 
controlled trials are now required.
VALVULAR HEART DISEASE
FIGURE 2: Myocardial scar in aortic stenosis.
Cardiovascular magnetic resonance late gadolinium enhancement allows detection of non-infarct pattern replacement fibrosis (white areas) in 
patients with severe aortic stenosis. This myocardial scar is associated with multiple markers of left ventricular decompensation and progresses 
rapidly until aortic valve replacement or transcatheter aortic valve implantation is performed. Although these interventions halt the development 
of further scar, replacement fibrosis that develops whilst awaiting intervention is irreversible, persists lifelong and is associated with dose-
dependent impact on long-term prognosis.
Watchful waiting
Rapid progression in myocardial 
scar once developed
Myocardial scar that patients develop whilst 
waiting for AVR persists for life and is 
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randomly assigned to undergo SAVR or TAVI with the self-
expanding CoreValve, Evolut-R, or Evolut Pro THV (Medtronic, 
USA). At 24 months, the estimated incidence of the primary 
endpoint (a composite of death or disabling stroke) was 5.3% 
in the TAVI group and 6.7% in the SAVR group [difference 
-1.4%; 95% Bayesian credible interval for difference (BCI) 
-4.9 - 2.1; posterior probability of non-inferiority >0.999]. At
30 days, TAVI patients had lower incidence of disabling stroke 
(0.5% vs. 1.7%; 95% BCI -2.4 - -0.2), acute kidney injury (0.9% 
vs. 2.8%; 95% BCI -3.4 - -0.5), and atrial fibrillation (7.7% vs. 
35.4%; 95% BCI -31.8 - -23.6), but higher incidence of mod-
erate or severe aortic regurgitation (3.5% vs. 0.5%; p< 0.05) and 
pacemaker implantation (17.4% vs. 6.1%; 95% BCI 8.0 - 14.7).
Alongside previous landmark studies, these results complete 
the evidence trail comparing TAVI and SAVR in all surgical 
risk categories and establish TAVI as a treatment for severe 
aortic stenosis irrespective of surgical risk. Furthermore, meta-
analysis of the 8 020 patients enrolled in the 7 randomised 
trials across the entire spectrum of surgical risk demonstrated 
a significant reduction of 1-year all-cause mortality with TAVI 
compared to SAVR (HR 0.88, 95% CI 0.78 - 0.99, p= 0.03) and 
lower risk of stroke (HR 0.81, 95% CI 0.68 - 0.98, p= 0.03; 
Figure 3).(26) These results have already translated into routine 
clinical practice in several European nations, as demonstrated 
by analysis of the German national aortic valve replacement 
registry (GARY).(27) Comparison of 14 487 SAVR patients and 
TRANSCATHETER INTERVENTION
The aortic valve
Transcatheter aortic valve implantation in low surgical 
risk patients
In 2019, an important evidence gap for TAVI was closed 
following publication of 2 landmark trials(24,25) comparing TAVI 
and surgical aortic valve replacement (SAVR) in patients at 
low surgical risk.
In the PARTNER 3 trial,(24)  1 000 patients with symptomatic 
severe aortic stenosis at low surgical risk were randomly as-
signed to undergo SAVR or TAVI with the balloon-expandable 
Edwards SAPIEN 3 transcatheter heart valve (THV). Those 
with a bicuspid valve or high-risk anatomical features for either 
procedure were excluded. The primary endpoint (a composite 
of death, stroke, or rehospitalisation) was tested for non-infe-
riority as well as superiority in the as-treated population. At 
1 year, the primary endpoint was significantly lower in the TAVI 
group than in the SAVR group (8.5% vs. 15.1%, p< 0.001 for 
non-inferiority; HR 0.54, 95% CI 0.37 - 0.79;  p= 0.001 for 
superiority), principally driven by reduced rates of rehospi-
talisation. There were no significant differences in major vascular 
complications, need for new permanent pacemaker implan-
tation, or more than mild paravalvular regurgitation.
Similarly, in the Evolut Low Risk Trial,(25)  1 468 patients with 
symptomatic, severe aortic stenosis at low surgical risk were 
FIGURE 3: Meta-analysis comparing transcatheter aortic valve implantation and surgical aortic valve replacement up to 
2-year follow-up for the primary outcome of all-cause mortality stratified by baseline surgical risk.
Reproduced with permission from Siontis GCM, et al.(26)
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Favours TAVI Favours SAVR
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6 062 TAVI patients at low surgical risk demonstrated supe-
rior in-hospital and 30-day survival for TAVI compared to 
SAVR (98.5% vs. 97.3%, p= 0.003; 98.1% vs. 97.1%, p= 0.014; 
respectively), with equivalent survival at 1 year (90.0% vs. 
91.2%, p= 0.16).
These favourable outcomes of TAVI indicate that surgical risk 
estimation is no longer the basis to guide the choice between 
TAVI and SAVR. Heart teams should now weigh clinical and 
anatomic characteristics to identify the best treatment option 
for individual patients, with transfemoral TAVI replacing SAVR 
as the default therapy for symptomatic severe aortic stenosis. 
Future research will need to address remaining uncertainties 
and options for further improvement in outcomes, including 
evaluation of TAVI in younger and asymptomatic patients 
(patients enrolled in the low-risk trials summarised above had a 
mean age of 74 years), assessment of THV durability using 
predefined clinical and echocardiographic assessment (5-year 
follow-up in the major randomised controlled trials has 
already demonstrated low rates of structural valve deteriora-
tion compared with SAVR, but longer-term data and larger 
patient numbers remain essential),(28-31) more detailed evalua-
tion of TAVI in patients with bicuspid aortic valve disease and 
concomitant coronary artery disease, continued measures to 
reduce the need for permanent pacemaker implantation, 
definition of the optimal short- and long-term regimes of 
antithrombotic therapy, and the institutional and operator 
standards required to achieve clinical outcomes that match 
those in the randomised controlled trials.(32)
Stroke and transcatheter aortic valve implantation
Stroke is a rare, but potentially devastating complication of 
TAVI that impacts quality of life, independent living and sur-
vival. Cerebral protection devices (CPDs) are intended to 
reduce the risk of cerebral embolism by capturing or deflecting 
debris during the TAVI procedure. A patient-level propensity-
matched analysis(33)  of the SENTINEL US IDE trial,(34)  the 
CLEAN-TAVI trial,(35) and the SENTINEL-Ulm study,(36) showed 
that TAVI with a dual-filter CPD (Claret Medical Inc., CA, USA) 
was associated with a signif icantly lower rate of procedural 
stroke compared with unprotected procedures (1.9% vs. 5.4%, 
odds ratio 0.35, 95% CI 0.17 - 0.72, relative risk reduction 
65%, p= 0.0028). However, this pooled analysis contained data 
from a non-randomised study(36)  and significant reduction in 
stroke with the use of CPD has yet to be shown in a major 
randomised trial.
Comparison of different transcatheter aortic valve 
implantation devices
Data directly comparing different TAVI devices are scarce. In 
the SCOPE I trial,(37)  the self-expanding Symetis ACURATE 
Neo valve (Boston Scientific, USA) was randomly compared 
to the SAPIEN 3 balloon-expandable valve (Edwards Life-
sciences, CA, USA) in 739 patients. The primary endpoint 
(all-cause mortality, any stroke, life-threatening or disabling 
bleeding, major vascular complications, coronary obstruction 
requiring intervention, acute kidney injury, rehospitalisation for 
valve-related symptoms or congestive heart failure (HF), valve-
related dysfunction requiring repeat procedure, moderate or 
severe prosthetic valve regurgitation, or prosthetic valve steno-
sis within 30 days of the procedure) occurred in 87 (24%) and 
60 (16%) of patients in the ACURATE Neo and SAPIEN 3 
groups, respectively. Non-inferiority criteria for the ACURATE 
Neo were not met [absolute risk difference 7.1% (upper 95% 
CI 12.0%), p= 0.42], and secondary analysis demonstrated 
that superiority of the SAPIEN 3 THV (95% CI for risk-
difference, -1.3% - -12.9%; p= 0.016) was driven by lower 
rates of acute kidney injury [3 (0.8%) vs. 11 (3%)] and moder-
ate or severe prosthetic aortic regurgitation [10 (2.8%) vs. 34 
(9.4%)]. Outcomes of the SCOPE II trial, comparing the self-
expanding Evolut (Medtronic, USA) and balloon-expandable 
SAPIEN 3 (Edwards Lifesciences, CA, USA) THVs in similar 
fashion are keenly awaited.
Valve-in-valve transcatheter aortic valve implantation in 
small surgical bioprostheses
Valve-in-valve TAVI in small surgical bioprostheses can result 
in high residual gradients that are associated with increased 
morbidity and mortality, and bioprosthetic valve fracture (BVF) 
improves residual gradients in this setting. In a multicentre 
registry of 75 patients,(38) BVF led to a final mean transvalvular 
gradient of 9.2 ±  6.3mmHg, with superior haemodynamic 
outcomes when BVF was performed immediately after (rather 
than before) THV implantation (8.1 ± 4.8mmHg vs. 16.9 ± 
10.1mmHg; p< 0.001). No aortic root disruptions or coronary 
occlusions were observed. This emerging concept and the 
associated BASILICA technique(39)  (electrocautery-induced 
laceration of the bioprosthetic valve leaflets in patients at 
high risk of coronary obstruction) require comparison with 
re-do surgery in patients with structural valve deterioration 
affecting small surgical bioprostheses.
The mitral valve
The conflicting results of the COAPT(40) and MITRA-FR(41) 
randomised controlled trials evaluating the safety and efficacy 
of transcatheter edge-to-edge repair using the MitraClip device 
in patients with symptomatic HF and moderate-severe sec-
ondary mitral regurgitation MR despite medical therapy, 
generated considerable discussion, with almost 20 editorial 
articles attempting to address subtle differences between 
the studies (Table 1) and their implementation in clinical prac-














showed no change in the findings of MITRA-FR, with no 
impact of MitraClip implantation on all-cause mortality or 
HF hospitalisation at 24-month follow-up,(44) while the benefits 
of MitraClip implantation in COAPT were even more pro-
nounced at 3-year follow-up [composite endpoint of death 
and HF rehospitalisation 58.8% vs. 88.1%, HR 0.48 (95% 
CI 0.39 - 0.59), p< 0.001; number needed to treat 3.4 (95% 
CI 2.7 - 4.6)].(45) A proposed pathophysiological model of 
“proportionate” and “disproportionate” MR(46) based upon 
the relationship between left ventricular end-diastolic volume 
and effective regurgitant orifice area, and its disruption in 
patients with ventricular dyssynchrony or papillary muscle dys-
function, may explain these disparities and awaits prospective 
validation. Cost-effectiveness analysis of COAPT at 2 years 
confirmed a higher cost of intervention overall ($73 416 vs. 
$38 345,  p< 0.001; predominantly related to the price of 
the MitraClip device), but acceptable economic value based 
upon current US thresholds (incremental cost-effectiveness 
ratio $40 361 per life-year gained, $55 600 per quality-adjusted 
life-year gained).(47)
Although large-scale clinical experience (>100  000 patients) 
and outcome data are only available for MitraClip edge-to-
edge repair, the Carillon Mitral Contour system (Cardiac 
Dimensions, Kirkland, WA, USA) was also investigated in a 
randomised sham-controlled study (REDUCE-FMR) among 
patients receiving guideline-directed medical therapy.(48) At 12 
months, indirect annuloplasty using this system was associated 
with a significant fall in MR regurgitant volume (the primary 
endpoint) accompanied by reduction in left ventricular vol-
umes and improvement in paired 6 minute walking distance 
and New York Heart Association (NYHA) functional class. 
However, the trial was not powered for clinical endpoints 
and the reported reduction in MR regurgitant volume (22%) 
TABLE 1: Key differences between the COAPT and MITRA-FR trials.
Reproduced with permission from Praz F, et al.(42)
Primary endpoint 
MITRA-FR 
All-cause death and 
hospitalisation for CHF at 1 year 
COAPT 
All hospitalisations for CHF 
within 2 years (including 
recurrent events)  
Key exclusion criteria   Heart failure severity 
Left ventricular dimensions 
Coronary artery disease 
Right ventricle 
Pulmonary disease   
NYHA class <II 
No exclusion criteria 
CABG or PCI performed within 1 month 
No exclusion criteria 
No exclusion criteria 
NYHA class <II 
ACC/AHA stage D heart failure 
LVESD >70mm 
Untreated coronary artery disease 
requiring revascularisation 
Right-sided congestive heart failure 
with moderate or severe right 
ventricular dysfunction 
COPD with home oxygen therapy or 
chronic oral steroid use 
Estimated or measured PAP >70mmHg   
Principal baseline characteristics  Number of patients screened 
Number of patients enrolled (ITT) 
Mean age (years) 
Mean LVEF (%) 
MR severity (EROA, cm2) 
Mean indexed LVEDV (mL/m2)   
450 
304 
70 ± 10 
33 ± 7 
0.31 ± 0.10 
135 ± 35 
1 576 
614 
72 ± 12 
31 ± 10 
0.41 ± 0.15 
101 ± 34   
Safety and effi cacy endpoints in 
the intervention arm  
Complicationsa (%) 
No implant (%) 
Implantation of multiple clips (%) 
Post-procedural MR grade ≤2+ (%)b 
MR grade ≤2+ at 1 year (%)b 
Hospitalization for CHF at 1 year (%) 
30-day mortality (%) 

















ACC = American College of Cardiology, AHA = American Heart Association, BNP = brain natriuretic peptide, CHF = congestive heart failure, COPD = chronic obstructive 
pulmonary disease, EROA = effective regurgitant orifice area, ITT = intention to treat, LVEF = left ventricular ejection fraction, LVESD = left ventricular end-systolic diameter, 
MR = mitral regurgitation, NT-proBNP = N-terminal pro brain natriuretic peptide, PAP = pulmonary artery pressure.
aMITRA-FR definition of pre-specified serious adverse events: device implant failure, transfusion or vascular complication requiring surgery, ASD, cardiogenic shock, cardiac embolism/
stroke, tamponade, urgent cardiac surgery.
b According to ESC/EACTS guidelines(5) in MITRA-FR and AHA/ACC Guidelines(43) in COAPT.
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was modest compared to that typically achieved following 
MitraClip edge-to-edge repair (60% - 70%).(49)
Meanwhile, the evidence supporting surgical intervention for 
secondary mitral regurgitation remains weak. Mitral annulo-
plasty, the most commonly used technique for surgical mitral 
valve repair, reduces MR, improves symptoms and results in 
reverse left ventricular remodelling in the short-term. How-
ever, it remains unclear whether these outcomes are durable 
or reduce mortality, although low rates of recurrent MR (28%) 
were recently reported at 10-year follow-up in a single-centre 
study.(50) Further high-quality studies will be required to refine 
selection criteria for the various medical and interventional 
treatment options in this high-risk group, to explore indica-
tions for MitraClip beyond the current evidence base, and to 
investigate the role of other transcatheter devices (annuloplasty, 
combined repair techniques, valve replacement).
The tricuspid valve
Transcatheter strategies for tricuspid disease remain in their 
early stages. Anatomical challenges include the large annulus, 
paucity of valve/annular calcification, adjacency of the right 
coronary artery, and fragility of the valve tissue. Current 
approaches under investigation in feasibility and early phase 
clinical trials include edge-to-edge repair, coaptation enhance-
ment, annuloplasty, heterotopic caval valve implantation, and 
percutaneous tricuspid valve replacement.(51) The supporting 
dataset is substantially smaller than for mitral interventions 
(which is itself limited), although promising early outcomes have 
been demonstrated with the MitraClip device.(52,53) Although 
recent studies have suggested potential advantages of trans-
catheter intervention compared with medical therapy,(54) major 
questions that need to be addressed by future trials include 
whether earlier intervention for tricuspid regurgitation may be 
beneficial, and whether combined mitral and tricuspid pro-
cedures improve procedural success and clinical outcomes.
The pulmonary valve
Twenty years since the first-in-human procedure, transcatheter 
pulmonary valve implantation (TPVI) has become the gold 
standard for treatment of pulmonary conduit dysfunction. In a 
VALVULAR HEART DISEASE













retrospective multicentre analysis of 845 patients undergoing 
TPVI with the Melody™ valve (Medtronic, USA),(55) the com-
posite endpoint of TPVI-related events (death, reoperation, 
or reintervention >48 hours after TPVI) occurred with an 
incidence of 4.2% per person per year (95% CI 3.7 - 4.9), 
confirming procedural efficacy in a large cohort of congen-
ital heart disease patients. Long-term risk of infective endo-
carditis is a concern in this setting and preventive measures 
are essential.(56)
INFECTIVE ENDOCARDITIS
The prospective EURO-ENDO registry of 3 116 adult patients 
(156 hospitals, 40 countries) with infective endocarditis con-
firmed persistent adverse outcomes (in-hospital mortality 17%, 
embolic complications 21%) despite advances in imaging, anti-
biotic therapy, and earlier surgery.(57)  Predictors of mortality 
included Charlson index, creatinine >2mg/dL, congestive HF, 
vegetation length >10mm, presence of abscess or cerebral 
complications, and failure to undertake surgery when indicated 
according to ESC guidelines. Management by a multidisci-
plinary team and early, aggressive surgery are essential to 
improve outcomes.
Diagnosis of prosthetic valve endocarditis is frequently diffi-
cult and ESC guidelines recommend  18F-fluorodeoxyglucose 
(18F-FDG) PET imaging in challenging cases.(58)  Among 173 
patients with left-sided endocarditis, diagnosis using  18F-FDG 
PET/CT was associated with a significantly higher rate of 
the primary endpoint [death, recurrent endocarditis, HF, non-
scheduled cardiovascular hospitalisation, new embolic event; 
HR 2.7 (1.1 - 6.7),  p= 0.04] in those with prosthetic valve 
infection, while moderate-intense valve uptake was associated 
with new embolic events [HR 7.5 (1.2 - 45.2), p= 0.03].(59)
CONCLUSIONS
Recent advances in the management of VHD achieved by 
open collaboration between cardiologists and cardiac surgeons 
have been remarkable. Ongoing innovation, a multidisciplinary 
Heart Team approach to the management of individual 
patients, and its delivery via a network of specialist valve 
centres,(60) will further transform the dismal prognosis associ-
ated with the condition. Worldwide extension of these 
advances to low- and middle-income countries (where VHD 
remains endemic) is the next urgent priority.
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